Aminoglycoside susceptibility of isolates with only an OXA-48-like (oxacillin-hydrolyzing β-lactamase) resistance mechanism (n = 20), determined using CLSI, EUCAST, and FDA breakpoints. S, susceptible; I, CLSI intermediate and EUCAST susceptible increased exposure categories; R, resistant; PLZ, plazomicin; AMK, amikacin; GEN, gentamicin; TOB, tobramycin.